CLINICAL SCENARIO

Chronic Osteoarthritis — High Analgesic Complexity

Bilateral knee OA with intersecting renal, gastrointestinal, cardiovascular, and polypharmacy constraints that collectively restrict the standard analgesic pathway.

Medication Review Objective

Evaluating analgesic safety under compound renal and GI constraint — balancing pain control against escalating polypharmacy and nephrotoxic risk

Progressive renal decline NSAID pathway closed Monitoring burden elevated Initiate acetaminophen TID

Anonymous · 68 y/o Female

Bilateral knee osteoarthritis — chronic, moderate-to-severe

CS-2026-00841

Pain (NRS)

6 / 10

Functional limitation — bilateral

eGFR

58 mL/min

CKD Stage 3a — declining trajectory

GI Risk

High

Prior peptic ulcer — documented

CV Risk

Moderate

BP 128 mmHg — managed

Active Medications

7 agents

Polypharmacy threshold exceeded

NSAID Pathway

CLOSED

Intolerance — oral and topical

Prior treatment failures: physiotherapy (incomplete), ibuprofen (GI adverse event), diclofenac (BP elevation). Two prior NSAIDs contraindicated. Opioid pathway avoided due to fall risk and sedation sensitivity.

Clinical Review Objective

Evaluate escalating NSAID-related renal and gastrointestinal risk in a high-complexity longitudinal medication-management scenario.

Primary Clinical Concern

Progressive renal decline under chronic analgesic exposure with increasing monitoring burden and worsening GI safety profile.

Suggested Pharmacist Action

Consider reducing NSAID exposure and initiating monitored alternative therapy with renal reassessment follow-up.

Complexity Indicators

CKD Stage 3a

eGFR 58 — limits nephrotoxic agents; trajectory unconfirmed pending recheck. Analgesic choices narrow further as function declines.

Polypharmacy

7 concurrent agents. Drug–drug interaction screening required. Adherence partially confirmed by self-report only.

GI Risk — High

Documented peptic ulcer history. NSAIDs and ASA contraindicated. COX-2 selectivity insufficient given renal + GI convergence.

Monitoring Burden

Requires renal function tracking (Week 6, then annual), pain reassessment (Week 2), and medication safety review at each contact.

Prior Treatment Failure

Two NSAID classes failed. Opioid class declined. Remaining pathway: acetaminophen TID → duloxetine escalation → surgical review.

Workflow Overview

Medication review workspace for a constrained analgesic pathway under compound GI, renal, and CV pressure. Parameters are pre-populated and all sections recalculate when values change.

Patient & Scenario Parameters

Review and modify live patient parameters — age, eGFR, GI risk, CV status, prior failures, adherence, and sedation sensitivity.

→

Clinical Status Summary

Automated clinical assessment bridging patient inputs and recommendations — clinical status, functional impact, symptom burden, risk profile, and overall assessment.

Pharmacist Recommendation

Primary recommendation with dosing, safety balance, confidence, and clinical rationale. Adapts to patient parameters in real time.

Renal vs Analgesic Risk Balance

Therapy risk balancing — GI safety vs analgesic efficacy, renal implications, deprescribing considerations, and what drove each decision.

4–6

Documentation · Progression · Monitoring Escalation

Clinical notes, longitudinal deterioration tracking, monitoring schedule, safety thresholds, and follow-up plan — all parameter-responsive.

7–8

Polypharmacy Risk Drivers · Therapy Evidence

Interaction burden review across the full medication list. Renal dose status, deprescribing considerations, and guideline citations.

What You Can Modify

eGFR — slide between 15 and 90 mL/min to observe renal pathway shifts

GI risk category — none, dyspepsia, active ulcer, recent bleed

Pain score (NRS) and CV risk tier to observe escalation thresholds

Prior treatment failure history — from none through multi-class

Adherence profile and sedation sensitivity — affects opioid and adjuvant decisions

Intolerance profile — modifies which drug classes remain available

All sections update in real time when parameters are changed. No page reload required.

NSAID pathway closed · GI + renal

Monitoring burden elevated · 3 active flags

Escalating monitoring concern

I — Clinical Context

II — Therapy Safety Assessment

III — Monitoring & Progression

IV — Intervention Review

V — Follow-up & Handoff

Medication Review Objective

Evaluating analgesic safety under compound renal and GI constraint — assessing acetaminophen adequacy and escalation threshold

Primary Concern Progressive renal decline · NSAID pathway closed

Suggested Action

Initiate acetaminophen TID — obtain baseline eGFR today

Review at Week 2 before escalation decision

Review Priority Monitor Escalating Monitoring Concern

Pharmacist Intervention

Medication Review — Analgesic Safety Assessment

CS-2026-00841

Suggested Intervention

Initiate today

Initiate acetaminophen TID — scheduled dosing, not PRN

Obtain baseline eGFR before Week 2 contact

Confirm adherence at Week 2 — do not escalate on PRN use

Maintain pantoprazole 40 mg — do not deprescribe

Risk drivers — why this matters now

If this contact is missed or delayed

Next contact: Week 2 — adherence + NRS + eGFR status

Action Pathway

Reassess pathway at Week 4 — escalation decision pending eGFR and adherence confirmation

Review Snapshot — Active Risks & Actions

Updated

Why this patient is high-risk

Compound GI + renal risk

Prior peptic ulcer · eGFR 58 · NSAID intolerance ×2

Monitor first — order today

Renal function — eGFR

Baseline today · Recheck Wk 2 + Wk 6 · Flag if drops >10%

No prior eGFR on file — trajectory unknown. Baseline required before any NSAID escalation decision.

Do not prescribe

NSAID pathway closed

GI risk + BP intolerance + age ≥65 (Beers)

Escalation trigger — watch for

NRS ≥8 or acetaminophen failure at Wk 4

Opens topical diclofenac gel pathway

Adherence — confirm at Wk 2

Inconsistent PRN — prescribe TID fixed

First objective check Week 2 · Subtherapeutic use confounds outcome

Self-reported only — do not interpret partial response as treatment failure until adherence confirmed

Current safety status

Favorable — within safe pathway

Acetaminophen: low systemic risk

Dominant Trade-off GI safety is the binding constraint — analgesic efficacy is being traded for gastrointestinal protection NSAID escalation deprioritized

Parameter Change — Reasoning Attribution

Why Changed —

Pharmacist Clinical Summary

Acetaminophen 500–1000 mg TID — initiate today

Intervention ready

CS-2026-00841

What to do — now

Start acetaminophen 500–1000 mg TID (fixed schedule). Not PRN — adherence to regular dosing is critical for outcome assessment.

NSAID pathway closed. Prior peptic ulcer + diclofenac BP response documented. Do not reopen without specialist review.

Obtain baseline eGFR today. No prior result on file. Required before any escalation decision at Week 4.

Review at Week 2: confirm TID adherence, NRS, GI tolerability. Do not escalate until adherence verified.

If uncontrolled at Week 4

Topical diclofenac gel Duloxetine 30–60 mg (neuropathic) Celecoxib low-dose (eGFR ≥50 only)

Active safety constraints

GI — Prior peptic ulcer · NSAIDs contraindicated

Maintain pantoprazole 40 mg — do not deprescribe. Any new GI symptoms (dark stool, epigastric pain): hold analgesic, urgent review.

Renal — eGFR 58, trend unknown

CKD Stage 3a. Acetaminophen ceiling: 3 g/day. Baseline eGFR required today. No NSAIDs until trend established at Week 6.

Adherence — first objective check Week 2

PRN use reported inconsistent. Prescribe fixed TID. Do not interpret partial early response as treatment failure before adherence confirmed.

Follow-up schedule — confirmed

Wk 2: adherence + NRS check · Wk 4–6: eGFR + LFT + escalation decision · Month 3: full medication review · Annual: metabolic panel + safety review

Step 1

Scenario Input

Patient parameters. Edit any value to update the medication review in real time.

Follow-up Context — Longitudinal Progression

Select a time-point to simulate patient status at that visit

Changes since last visit

Reasoning implication

Patient Parameters — Live Edit

Workflow updates when parameters change

Renal (eGFR) Trend unknown

58 mL/min

Mild impairment

No prior eGFR on record — trajectory cannot be confirmed; borderline stage G2/G3a

GI Bleeding Hx

Prior peptic ulcer

High risk

Blood Pressure

128/76 mmHg

Controlled

Cardiovascular Risk

Moderate

Hypertension

Pain Severity

6 / 10

Moderate

Age

68 years

≥65 flag active

Failed Therapies Incomplete hx

2 NSAIDs failed

Intolerance documented

Duration of prior trials unclear — early discontinuation may not reflect true therapeutic failure

Adherence Self-reported

Inconsistent PRN

Concern noted

Reliability uncertain — not verified by pharmacy or pill count at this visit

Sedation Risk

High concern

Patient refuses sedation

Med Intolerance Partial record

NSAIDs: GI + BP

Documented × 2

Diclofenac BP response chart-reported; ibuprofen GI event details sparse — source record not retrieved

Scenario complexity

72 — High-complexity multifactorial profile. Multiple active contraindications.

Patient Context

Created May 15, 2026 · by Mikhail Evteev

68-year-old female

Chronic bilateral knee osteoarthritis · Long-term pain management · Activity increasingly limited

High GI risk Prior peptic ulcer (2yr) Age ≥65 Mild renal impairment (eGFR 58) Hypertension controlled Mobility preservation priority NSAID intolerance × 2 Low polypharmacy burden

Condition

Knee osteoarthritis
Chronic · Bilateral

Pain severity

Moderate (6/10)

Moderate

Key risk factors

Prior peptic ulcer (2 yrs)
Age ≥65
Controlled hypertension
eGFR 58 — mild CKD (stage G2)

Current medications

Amlodipine 5 mg
Pantoprazole 40 mg
+ Acetaminophen proposed (3rd agent)
No anticoagulants · No corticosteroids Low polypharmacy burden — interaction risk manageable

Previous therapies tried

Ibuprofen 400 mg — discontinued (GI discomfort, epigastric pain after 3 weeks)

Diclofenac oral 50 mg — discontinued (blood pressure elevation +18 mmHg systolic)

Physiotherapy (8 sessions) — partial functional benefit; patient unable to continue due to transport access

Topical diclofenac gel — tried briefly; inconsistent use (patient reports difficulty applying to both knees)

Duration of NSAID trials not fully documented — early GI response may reflect inadequate PPI co-prescribing rather than true class intolerance. Clinical judgement required before closing NSAID pathway on this basis alone.

Adherence & tolerance notes

Good adherence to amlodipine and pantoprazole — confirmed by pharmacy records

Inconsistent adherence to PRN analgesics — reports "forgetting" when pain is mild

Previous GI intolerance to oral NSAIDs documented in chart — epigastric symptoms within 2–3 weeks of use

Expressed strong concern about sedating agents — "doesn't want to feel foggy"

Prefers fewest possible daily medications — currently managing 2 daily drugs

Adherence to analgesics self-reported only. No pill count, blister pack review, or pharmacy dispensing frequency check available. Actual exposure pattern may differ from reported use.

Patient preferences Mobility preservation priority Oral over topical Minimize medications Open to escalation Concerned about GI risk No sedation Avoid injections

Activity limitations

Difficulty descending stairs — pain worsens on stairs (reported at last visit)
Cannot walk >10 minutes without stopping — functional limitation progressing over 6 months
Unable to kneel or squat — bilateral joint involvement
Patient reports pain is now limiting social activities and independent mobility

Treatment goals Meaningful pain relief (NRS ≤3) Restore stair-climbing & walking >15 min Minimize GI & renal risk Maintain social independence

Scenario data is used to generate decision output. All inputs should reflect the actual patient context.

Clinical Status Summary

Patient Assessment — Day 1

Clinically Stable

Clinical Status

Stable

No acute deterioration

Functional Impact

Moderate

Stair use and walking limited

Symptom Burden

Moderate–High

NRS 6/10 · Bilateral

Risk Profile

Moderate–High

GI + renal + age constraints

Treatment Pathway

Constrained

NSAID & opioid closed

Intervention Urgency

Prompt

Initiate today · Review Wk 2

Overall Assessment

Patient remains symptomatic but clinically stable. Pain is moderate-to-severe with progressive functional limitation. Analgesic options are significantly restricted by compound GI, renal, and cardiovascular constraints. First-line treatment initiation is appropriate today — acetaminophen TID provides the best achievable safety-efficacy balance within the current constraint profile.

Why this recommendation follows

GI risk binding Renal monitoring required NSAID pathway closed ×2 Acetaminophen: lowest systemic risk ACR 2023 aligned

Clinical Impression Day 1

Clinical direction

Step 2

Decision Output

Recommended therapy with dosing, alternatives, and decision rationale.

Primary treatment recommendation · First-line

Acetaminophen
(Paracetamol)

Preferred · First-line

GI risk is the binding constraint. Prior peptic ulcer + two documented NSAID intolerances close the NSAID pathway entirely. Acetaminophen provides adequate first-line analgesia without GI or renal burden. eGFR 58 (CKD Stage 3a) reinforces NSAID avoidance. Aligns with ACR 2023, Beers Criteria (≥65), and NICE CG177. Oral route preferred per patient history of inconsistent topical use.

Why this recommendation changed

—

ACR Guideline Aligned · 2023 NICE Guidance Supported Beers Criteria Compliant · AGS 2023 Moderate–High Evidence Long-term safety uncertainty >2yr GI risk literature considered

82%

High confidence

Supported by ACR/EULAR guidelines · Multiple RCTs

Guideline-supported Evidence consistent Limited long-term data >2yr Moderate analgesic effect

Alternative options

Topical NSAIDs Conditional
Localized pain · Lower systemic risk

Avoid

High-dose NSAIDs Avoid
GI risk outweighs benefit

Primary decision drivers

High GI risk · Age ≥65 · Prior NSAID intolerance · Mild renal impairment (eGFR 58) · Long-term use requirement · Mobility preservation goal

Recommended · First-line

Acetaminophen

Best balance

First-line for pain relief with the most favorable GI and CV safety profile in this patient. Dose: 500–1000 mg TID, max 3g/day (older adult).

ACR Guideline Aligned Cochrane-reviewed efficacy Preferred in Beers Criteria context Multiple RCT support

Most favorable GI safety profile — avoids NSAID-related GI complications entirely

Well tolerated in adults ≥65 · Low systemic risk · Does not affect BP

Suitable for long-term use · High adherence · Low cost

Patient-preferred oral formulation · Aligns with patient's stated preferences

Why not other options?

Competing therapy deprioritization rationale

High-dose NSAIDs Avoid

Deprioritized due to compound contraindication profile in this patient.

Elevated GI bleeding risk — prior peptic ulcer + documented NSAID-induced GI intolerance (ibuprofen, diclofenac both failed)

Hypertension interaction risk — previous diclofenac caused +18 mmHg systolic elevation

Renal monitoring concern — eGFR 58 at baseline; NSAIDs impair renal perfusion and cannot be safely initiated

Age ≥65 — Beers Criteria recommends against NSAIDs unless all alternatives exhausted

Opioid analgesics Avoid

Opioid pathway not appropriate for chronic OA pain management in this profile.

Sedation risk — patient explicitly refuses sedating agents; fall-risk in age ≥65 is a documented safety concern

Dependency considerations — chronic opioid use requires specialist oversight not currently in plan

Renal metabolite clearance — eGFR 58 limits elimination of opioid metabolites (esp. morphine-6-glucuronide)

No clinical indication at this stage — moderate OA pain without multimodal failure

Topical NSAIDs Conditional

Considered adjunctive rather than primary strategy at this stage.

Bilateral knee involvement — topical coverage limited for bilateral application; compliance concern documented

Patient preference — oral route preferred; previous topical trial showed inconsistent adherence

Analgesic ceiling — lower analgesic power than systemic options for moderate-severity OA (NRS 6/10)

May be added as adjunct if oral monotherapy inadequate at Week 2 or 4

Duloxetine Escalation

May be considered later — not first-line in current scenario.

Sedation risk in older adult — fall-risk profile; patient expressly refuses sedating agents

Not first-line for OA without neuropathic features — reserve for neuropathic component or failed multimodal trial

SNRIs require titration period — 4–6 weeks to assess efficacy; not suitable for acute escalation need

Appropriate escalation trigger: if neuropathic features emerge or acetaminophen + topical NSAID inadequate after Week 8

Treatment options

Alternative

Topical NSAIDs

Consider for localized knee pain as adjunct to acetaminophen. Lower systemic exposure; favorable GI and CV profile.

Why not primary?

Limited coverage for bilateral knee pain

Patient prefers oral route — compliance concern

Lower analgesic ceiling than systemic options

Conditional

Escalation option

Duloxetine

Consider if neuropathic features emerge or acetaminophen response inadequate after 4 weeks. SNRIs show efficacy in OA pain.

Why not earlier?

Sedation risk in older adult — fall-risk profile

Patient-expressed concern about sedating agents

Reserve for neuropathic component or escalation

Escalation · Monitor

Conditional

Low-dose NSAID + PPI

Fallback if acetaminophen proves insufficient. Must include PPI cover. Close GI monitoring required. Avoid long-term use.

Why deprioritized?

Residual GI bleeding risk even with PPI cover

Prior peptic ulcer — compounded risk

Hypertension interaction risk with NSAIDs

Conditional · GI monitored

Avoid

Opioid analgesics

Not appropriate as analgesic strategy for chronic OA pain in this patient profile. Risk-benefit unfavorable.

Opioid pathway avoided because

Sedation risk — patient expressly refuses sedating agents; fall-risk in age ≥65

Dependency considerations — chronic use in older adult is contraindicated without specialist oversight

Mild renal impairment (eGFR 58) — limits opioid metabolite clearance

No indication for opioid-class analgesic in moderate OA without prior multimodal failure

Contraindicated · Do not initiate

Avoid

High-dose NSAIDs

GI complication risk substantially outweighs analgesic benefit. Prior NSAID-induced GI intolerance, peptic ulcer, age ≥65, and mild renal impairment are compounding contraindications.

Deprioritized — all three criteria met

Elevated GI bleeding risk — prior peptic ulcer + documented NSAID GI intolerance (ibuprofen, diclofenac both failed)

Hypertension interaction — previous diclofenac caused +18 mmHg BP elevation; amlodipine efficacy may be impaired

Renal monitoring concern — eGFR 58; NSAIDs reduce renal perfusion, contraindicated if eGFR deteriorates to <45

Beers Criteria flag — explicit recommendation against in adults ≥65 unless all alternatives exhausted

Poor fit · Contraindicated

Rationale for recommendation

Clinical reasoning

High GI bleeding risk (prior peptic ulcer) substantially increases the probability of NSAID-related GI complications including bleeding, ulcers, and perforation. [1, 2]

Age ≥65 amplifies GI bleeding risk and drug sensitivity. AGS Beers Criteria (2023) explicitly recommends against NSAIDs in older adults unless alternatives are inadequate. [3]

Long-term pain control goal favors an agent with an acceptable chronic safety profile. Acetaminophen provides adequate analgesia with the lowest systemic risk in this patient context. [4]

Controlled hypertension in an older patient is a secondary reason to avoid NSAIDs, which can raise blood pressure and impair the efficacy of antihypertensive therapy. [5]

Treatment comparison

Evidence basis ACR Guideline Aligned Moderate–High Evidence GI risk literature considered Beers Criteria 2023

Key trade-offs at a glance

Option	Analgesic efficacy	GI safety	CV safety	Decision state
Acetaminophen	Moderate	Very good	Good	Best balance
Topical NSAIDs	Low–Moderate	Good	Good	Conditional
Low-dose NSAID + PPI	High	Moderate ↑ risk	Moderate	Conditional
High-dose NSAIDs	High	Poor	Moderate	Poor balance

Not a substitute for clinical judgment. Clinstrux supports decisions but does not replace clinician expertise.

Step 3

Trade-offs & Drivers

Therapy risk balancing — why each option was selected, modified, or excluded for this patient.

Decision state matrix

Option	Analgesic	GI safety	CV safety	Convenience	Decision state
Acetaminophen	Moderate	Very good	Good	Excellent	Best balance
Topical NSAIDs	Low–Moderate	Good	Good	Moderate	Conditional
Low-dose NSAID + PPI	High	Moderate	Moderate	Moderate	Escalation
Duloxetine	Moderate	Good	Moderate	Moderate	Adjunct
High-dose NSAIDs	High	Poor	Moderate	Complex	Avoid

Key decision drivers

Driver	Impact	Rationale & evidence
GI bleeding riskHigh	Strong negative	Prior peptic ulcer significantly increases NSAID-related GI risk. Strongest driver against NSAID selection. ACG GuidelineBeers Criteria
Age ≥65High	Strong negative	Older age amplifies GI bleeding risk and drug sensitivity. Beers Criteria flags NSAIDs in adults ≥65. Beers 2023
Long-term useModerate	Moderate	Chronic pain requires sustained therapy. NSAIDs not recommended for chronic use in this risk profile. ACR Guideline
Renal functionModerate	Moderate caution	Baseline eGFR 58 (CKD stage G2). NSAIDs contraindicated if eGFR <45 — currently marginal. NSAID-induced renal impairment would eliminate escalation options entirely. KDIGO GuidelinesBNF Renal guidance
Therapy failure historyHigh	Strong evidence	Two prior NSAID trials (ibuprofen, diclofenac) both discontinued due to GI intolerance and BP elevation. Direct clinical evidence that NSAID pathway is not viable for this patient. Chart reviewPatient history
CV riskModerate	Moderate	Controlled hypertension in older patient. NSAIDs can raise BP and impair antihypertensive efficacy. Previous diclofenac raised BP by +18 mmHg — documented. ESC GuidelinesPatient chart

Shared decision considerations

Patient-centered reasoning

Patient prioritizes mobility and staying physically active — pain control supports this goal

Prefers oral medication over topical application — acetaminophen aligns with this preference

Wants to minimize total daily medications — monotherapy is appropriate at this stage

Concerned about GI side effects — acetaminophen directly addresses this concern

Open to reassessment and stepwise escalation if adequate relief is not achieved

Drivers are weighted based on clinical impact for this patient scenario. Weighting should be reviewed when scenario parameters change.

Step 4

Clinical Notes

Clinician notes, context, and follow-up planning for this case.

Patient context — May 17, 2026 · M. Evteev

68-year-old female presenting with progressive bilateral knee pain over 6 months. Pain now 6/10 at rest and 8/10 with movement. Functional status declining — reports stair use becoming impractical and walking limited to <10 minutes.
Peptic ulcer 2 years ago — healed, no active GI symptoms. Currently on pantoprazole 40 mg; GI symptom-free at presentation. GI risk elevated by ulcer history — any NSAID use carries meaningful bleeding risk.
Renal function: eGFR 58 ml/min/1.73m² (CKD Stage G2 — mild impairment). Baseline creatinine documented. eGFR trajectory stable over 6 months. NSAID use would require renal monitoring; trajectory to <45 would contraindicate NSAIDs entirely.
Cardiovascular: controlled hypertension on amlodipine 5 mg. BP 128/76 at today's visit. Previous diclofenac trial caused sustained BP elevation (+18 mmHg systolic) — documented, relevant to escalation decisions.

Functional status & activity limitations

Stair use now avoided due to pain — cannot descend stairs without significant discomfort. Pain worsens immediately on stair contact. Reports avoiding her building's staircase entirely.
Walking distance limited to under 10 minutes before pain forces rest — functional decline progressive over 3–4 months. Patient notes this is now affecting grocery shopping and social visits.
Cannot kneel or squat — bilateral involvement. Getting up from low seats painful.
Pain is now limiting social activities and independent mobility. Patient expressed distress about loss of independence — this is her primary motivation to seek treatment change.

Therapy history & prior treatment failures

Ibuprofen 400 mg TID — discontinued after 3 weeks: epigastric pain, nausea. GI intolerance well-documented in chart.
Diclofenac 50 mg twice daily — discontinued: sustained blood pressure elevation (+18 mmHg systolic, confirmed on 3 readings over 2 weeks). Amlodipine dose increased during this trial but BP remained elevated.
Physiotherapy: 8 sessions with home program — partial functional benefit reported. Unable to continue due to transport access difficulties. Home-based program may be appropriate for future referral.
Topical diclofenac gel — used intermittently for 6 weeks. Inconsistent adherence: patient reports difficulty applying to both knees independently. Right knee pain greater than left.
Paracetamol 500 mg PRN (self-administered, not regular) — partial benefit. Fixed-schedule TID use has not been tried previously.

Adherence & medication preference

Adherence to amlodipine and pantoprazole: good (confirmed by pharmacy refill records — no missed fills over 6 months).
Adherence to PRN analgesics: inconsistent — patient reports taking analgesics only when pain is "bad enough." Has not used a fixed dosing schedule. Counselling on fixed schedule rationale provided today.
Patient expressed strong reluctance regarding sedating agents: "I don't want to feel foggy." This directly limits neuromodulator options (duloxetine, gabapentinoids) and opioid pathway.
Prefers oral route — has found topical application difficult to manage independently at bilateral knee sites.

Clinician assessment

Mobility preservation is the primary functional goal. Given documented NSAID GI intolerance (both ibuprofen and diclofenac), prior peptic ulcer, BP-elevating response to diclofenac, mild renal impairment (eGFR 58), and age ≥65 (Beers Criteria) — NSAID pathway is not appropriate as first-line. Acetaminophen 1g TID fixed schedule remains the safest evidence-supported first-line option. The patient has not previously trialed fixed-schedule acetaminophen, which is the primary therapeutic question to resolve over the next 4 weeks.

Follow-up plan — May 17, 2026 · M. Evteev

Week 2 — Pain & function check: Assess NRS score (compare to baseline 6/10). Stair-climbing status — key functional milestone. Confirm TID adherence; ask specifically about GI symptoms (epigastric pain, nausea). If pain unchanged (NRS ≥6) → add topical diclofenac gel (right knee).
Week 4 — Formal escalation review: Full pain + function review. If NRS ≥5 or no meaningful walking improvement → escalation decision required. LFT (ALT/AST) if acetaminophen maintained at 3g/day. Repeat eGFR (baseline 58) — flag if any decline. BP check.
Week 6 — Labs checkpoint: eGFR, creatinine, LFT. Renal trajectory review. If eGFR <50 → reclassify renal risk and avoid any NSAID. BP check: SBP >160 → review co-prescribing, amlodipine dose discussion.
Week 8 — Comprehensive review: Pharmacological and functional review. Mobility outcomes, medication satisfaction, adverse effect profile. Physiotherapy progress. Orthopedic referral threshold assessment — if conservative ceiling reached.

Escalation triggers — document at each visit

GI symptoms at any stage → halt escalation. Review pantoprazole. Do not add NSAID until GI stable.
BP >160 systolic with any NSAID → discontinue immediately. Reassess amlodipine.
eGFR <50 → NSAID contraindicated. Reduce acetaminophen if eGFR <30. Nephrology if <40.
Neuropathic features (burning, radiating pain, night pain) → consider duloxetine 30 mg. Counsel on sedation risk before prescribing.
Functional decline despite optimized pharmacotherapy → physiotherapy referral (home-based) + orthopedic evaluation for TKA candidacy.

If treatment goals are met

NRS ≤3 + stair use restored + walking >15 min + social independence maintained → maintain current regimen.
Step down monitoring to 3-monthly. Do not escalate unnecessarily. Reinforce fixed TID schedule.
Annual eGFR review. Annual medication safety review.

Team notes — May 17, 2026

For nursing: Patient has history of inconsistent adherence to PRN analgesics. Reinforce fixed TID dosing schedule for acetaminophen — not as-needed. Provide written instructions.
For pharmacy: Previous NSAID GI intolerance documented. Pantoprazole 40 mg ongoing — ensure no substitution to lower-dose formulation. Flag if any NSAID prescribed by other services.
For physiotherapy (if referral proceeds): Bilateral knee OA. Primary goal is mobility restoration — stair use and sustained walking >15 minutes. Transport barrier to clinic attendance — please assess suitability for home program.
Renal flag: eGFR 58 at baseline. If any NSAID initiated by any team member — renal function must be rechecked at 2 weeks. Alert prescribing clinician if eGFR drops <50.

These notes are for clinician reference only and are not used to generate recommendations. Do not include patient identifiers.

Step 5

Treatment Progression

Follow-up checkpoints, escalation triggers, and therapy adaptation over time.

Initial strategy

Acetaminophen monotherapy

Day 1 — fixed schedule

First reassessment

Week 2

Pain score, stair use, GI tolerability

Escalation decision

Week 4

If NRS ≥5 → escalate

Success threshold

NRS ≤3 + stair use

Maintain and step-down monitoring

Longitudinal treatment pathway

Reassessment timeline — adaptive management logic

Day 1

Treatment initiation Initiation

Initiate acetaminophen 1g TID (max 3g/day — older adult dose ceiling). Fixed schedule — not PRN. Counsel patient on dose ceiling and alcohol avoidance. Confirm pantoprazole 40 mg ongoing. Document baseline NRS 6/10 and stair-climbing impairment. Reinforce that effect may take 1–2 weeks to become meaningful.

Data gapNo prior eGFR on record. Obtain baseline renal labs at initiation — this visit — rather than deferring to Week 6. A single historical eGFR is needed to establish trajectory direction before any future escalation decision is made.

Week 2

Initial pain & function review Checkpoint

Reassess NRS pain score — compare to baseline 6/10. Stair-climbing function: restored, unchanged, or worsened? Walking distance >10 min? Confirm adherence to fixed TID schedule. Ask specifically about GI tolerability — epigastric pain, nausea.

If NRS ≥6 or no functional improvement → add topical diclofenac gel (right knee priority — higher pain burden side)

If GI symptoms emerge (epigastric pain, nausea) → hold escalation. Review pantoprazole adequacy. Do not add any NSAID until GI stable.

If adherence suboptimal (PRN rather than TID) → reinforce fixed schedule. Do not escalate dose before confirming adherence.

If NRS ≤3 and stair use improved → maintain regimen. No dose escalation required. Review again at 4 weeks.

CautionAdherence has not yet been independently verified. Do not interpret persistent pain at Week 2 as treatment failure until fixed-schedule adherence is confirmed. Escalation based on apparent non-response may reflect adherence failure rather than pharmacological inadequacy.

Week 4

Formal escalation decision point Escalation Review

Formal pain + functional review against 4-week milestone. Compare NRS to baseline. Has walking distance improved (target: >15 min sustained)? Assess stair function. Review adherence consistency. Evaluate GI status before any escalation.

If pain persists (NRS ≥5) and GI stable → escalate to topical diclofenac gel adjunct. Continue acetaminophen. Reassess bilateral coverage need at Week 6.

If neuropathic features emerge (burning, radiating, night pain) → initiate duloxetine 30 mg once daily. Monitor for sedation and fall risk. Titrate to 60 mg after 2 weeks if tolerated.

If mobility continues declining despite adequate analgesic trial → physiotherapy referral (home-based program — address transport barrier). Do not delay referral further.

If mobility meaningfully restored (stair use, walking >15 min) → maintain current regimen. Reduce review frequency to 6–8 weekly.

PrerequisiteEscalation at Week 4 requires confirmed eGFR result from this visit. Without renal baseline established at Day 1, eGFR trend cannot be determined and topical or systemic NSAID escalation should be deferred until labs are available. Do not escalate on clinical grounds alone when renal trajectory is unknown.

Week 8

Comprehensive treatment review Checkpoint

Full pharmacological and functional review. Reassess pain severity, mobility outcomes, medication safety (BP, eGFR, liver function), and treatment satisfaction. Physiotherapy progress review. Orthopedic referral threshold discussion — if conservative management ceiling is approaching.

If BP worsens (>160 systolic) → discontinue any NSAID component immediately. Reassess amlodipine dose. Refer cardiology if uncontrolled.

If pain still inadequate (NRS ≥5) → consider low-dose celecoxib + continued PPI under close GI + renal monitoring. 2-week trial. Confirm eGFR ≥50 before initiation.

If functional decline despite optimized pharmacotherapy → orthopedic consultation for surgical candidacy assessment (TKA discussion).

If functional goals met (NRS ≤3, walking >15 min, stair use restored, social independence maintained) → step-down to 3-monthly monitoring. Current regimen maintained.

3 Months

Stable-phase longitudinal review

Every 3–6 months in stable phase: reassess pain score, functional independence, medication safety profile. Repeat eGFR annually. Maintain pain diary review at visits. Assess whether activity and social engagement has been restored.

If functional decline resumes despite pharmacotherapy → refer to physiotherapy (home-based program) and orthopedic evaluation for surgical candidacy

If eGFR continues declining trend → nephrology co-management. Avoid all NSAIDs. Reduce acetaminophen to 2g/day if eGFR <30.

If sustained improvement maintained → continue current regimen. Annual medication safety review. Reinforce adherence to fixed schedule at each visit.

Escalation pathway summary

Condition-triggered escalation rules

→Pain uncontrolled at Week 2 (NRS ≥6) → add topical diclofenac gel (right knee priority). Reassess bilateral symptom pattern at Week 4.

→Inadequate relief at Week 4 (NRS ≥5) → consider low-dose celecoxib + PPI with close GI and renal monitoring. Confirm eGFR ≥50 before initiation.

→Neuropathic features emerge → initiate duloxetine 30 mg as adjunct. Titrate to 60 mg if tolerated. Monitor for sedation — patient expressly refuses sedating agents. Reassess at 3 weeks.

→GI symptoms at any stage → halt NSAID escalation. Review pantoprazole adequacy (consider dose increase or H. pylori retest). No NSAID addition until GI stability confirmed.

→BP worsens (>160 systolic) → discontinue any NSAID component immediately. Reassess amlodipine dose.

→eGFR drops below 50 → reclassify renal risk. All NSAID use absolutely contraindicated. Reduce acetaminophen to 2g/day as precaution. Nephrology co-management if eGFR <40.

→Functional decline despite optimized pharmacotherapy → refer to physiotherapy (home-based, address transport barrier) and orthopedic evaluation for TKA candidacy.

✓If mobility improves (stair use restored, walking >15 min, NRS ≤3, social independence maintained) → maintain current regimen. Step-down monitoring to 3-monthly. Reinforce fixed TID schedule.

Treatment progression should be reassessed at each encounter. Pathway logic adapts to new clinical information — escalation and de-escalation decisions require clinical judgment at point of care.

Step 6

Monitoring & Safety

Lab schedule, safety thresholds, and follow-up actions by timepoint.

Parameters tracked

Active monitoring items (incl. renal)

Next review

2 weeks

Pain score, stair function & tolerability

Baseline labs status

Pending

No prior eGFR on record — obtain at Day 1 visit to establish renal trend

Safety monitoring schedule

Checkpoint

Labs / tests

Clinical assessment

Safety action trigger

Baseline (Day 1)

eGFR Not yet obtained, creatinine, LFT, BP 128/76

NRS 6/10, stair function, GI status, weight

Baseline eGFR required at this visit — no prior result on file. Do not defer. Renal trend undetermined without this result.

Week 2

—

NRS, stair use, GI tolerability, adherence (TID vs PRN) First objective adherence check

GI symptoms → hold escalation. Adherence gap → reinforce before escalating. Do not interpret partial response as treatment failure before adherence confirmed.

Week 4–6 ★

LFT (ALT/AST), eGFR, creatinine, BP

Pain + function review, walking distance, adherence

eGFR <50 → no NSAID. ALT >3×ULN → reduce dose. SBP >160 → stop NSAID

Month 3

eGFR, creatinine, LFT if on high-end dose

Comprehensive review: pain, mobility, BP, adherence, satisfaction

Goals met → step-down to 3-monthly. Decline → ortho referral

Annual

Full metabolic panel, eGFR, LFT

Medication review, ADL function, falls risk, mobility assessment

Annual medication safety review. Reassess surgical threshold.

Detailed monitoring parameters

Parameter	What to monitor	Frequency	Escalation trigger	Priority
Pain & function	NRS pain score (0–10), stair-climbing ability, walking distance (target: >15 min)	Every 2–4 weeks	NRS ≥5 after 4 weeks or functional decline → escalate regimen	High
GI symptoms	Epigastric pain, black stools, nausea, hematemesis. Documented NSAID GI intolerance — early detection priority.	Ongoing · Every visit	Any GI bleeding → stop all analgesics, refer urgently. Epigastric pain → hold escalation	High
Renal function	eGFR, creatinine — baseline 58 (CKD G2). Mild impairment present at initiation. Track trajectory.	Baseline, then 6-week, then 3-monthly	eGFR <50 → avoid all NSAIDs. eGFR <30 → nephrology referral	High
Liver function	ALT, AST — if acetaminophen at ≥2.5g/day or alcohol use reported	Baseline, then 4–6 weeks	ALT >3× ULN → reduce dose to 2g/day. If persists → hepatology	Moderate
Blood pressure	Systolic/diastolic — especially if NSAID escalation initiated. Previous diclofenac caused +18 mmHg.	Every 4–6 weeks	SBP >160 → review any NSAID co-prescribing. Discontinue NSAID if BP uncontrolled	Moderate
Adherence	Confirm fixed TID schedule maintained (not PRN use). History of inconsistent PRN adherence documented.	Every visit	Inconsistent use → reinforce fixed schedule before dose escalation. Consider blister packaging.	Moderate
Sedation / falls	Dizziness, falls risk, sedation — particularly if duloxetine or any adjunct initiated	Ongoing · Patient-reported	Any fall or sedation complaint → review all medications. Discontinue sedating agent.	Moderate
Mobility outcome	Stair-climbing restored, walking >15 min, social independence maintained. Patient-reported outcome measure.	Every 4–8 weeks	Continued functional decline despite pharmacotherapy → physiotherapy referral + orthopedic evaluation	Routine

Renal dosing implications — current eGFR

Acetaminophen ceiling

3 g/day (eGFR 45–59)

Older adult dose ceiling at eGFR 58. Reduce to 2 g/day if eGFR drops below 30.

NSAID status (renal)

Avoid (eGFR + intolerance)

Prostaglandin-dependent renal perfusion increasingly at risk below eGFR 60. Combined with documented intolerance — contraindicated.

Opioid / adjunct risk

Metabolite accumulation risk

eGFR 58 — morphine-6-glucuronide accumulation begins below eGFR 50. Avoid opioids unless unavoidable. Gabapentinoids require dose reduction at eGFR <60.

Not appropriate if (contraindications & warnings)

✕ Active GI bleeding or active peptic ulcer — documented prior ulcer (2yr); monitor actively

✕ Severe hepatic impairment (Child–Pugh C) — limit acetaminophen to 2g/day or avoid

✕ eGFR <30 — avoid NSAIDs entirely; acetaminophen dose reduction required

✕ Uncontrolled hypertension (SBP >160) — avoid NSAIDs until BP controlled on amlodipine

✕ Known NSAID hypersensitivity or prior severe NSAID-induced reaction — prior GI intolerance documented (ibuprofen, diclofenac)

✕ Sedating agents (opioids, high-dose duloxetine) without fall-risk assessment — patient profile and expressed preference mandate caution

Monitoring parameters should be adapted to individual patient context. Reassess the plan as new information becomes available.

Step 7

Polypharmacy & Interactions

Interaction burden, renal dose adjustment, and deprescribing considerations for the current regimen.

Medication safety overview — current regimen Moderate burden

Active medications

3 drugs

Amlodipine, pantoprazole + acetaminophen proposed. Polypharmacy threshold not yet crossed.

Renal dose status

1 adjustment active

Acetaminophen ceiling applies at eGFR 58. NSAIDs excluded from regimen — renal constraint active.

Interaction burden

1 monitor-level pair

Amlodipine–NSAID interaction prevented by NSAID exclusion. Acetaminophen + pantoprazole: no clinically significant interaction.

Current medication burden — interaction & renal risk profiling

Regimen-level interaction & dose review

Drug / Indication

Interaction profile

Renal dose status

Deprescribing

Amlodipine 5 mg daily

CCB · Antihypertensive

⚠ NSAID: BP elevation risk

NSAIDs reduce antihypertensive efficacy by 3–5 mmHg systolic on average. Prior diclofenac caused +18 mmHg in this patient — documented. NSAID avoidance removes this risk entirely.

✓ No interaction: acetaminophen

Acetaminophen does not antagonize CCB antihypertensive effect — safe combination.

No adjustment required

Hepatically metabolised (CYP3A4). Renal impairment does not alter dosing. Safe across all eGFR ranges.

Maintain

Ongoing hypertension indication. BP controlled at 128/76. Essential to maintain — deprescribing would unmask cardiovascular risk and increase NSAID danger.

Pantoprazole 40 mg daily

PPI · GI prophylaxis

✓ No significant interactions

No clinically significant interaction with acetaminophen or amlodipine at standard doses. CYP2C19 interaction with clopidogrel would apply if antiplatelet added — flag if regimen changes.

ℹ Celecoxib: dose-dependent PPI requirement

If celecoxib considered at escalation: 40 mg pantoprazole mandatory concurrently — already prescribed. Review adequacy at that stage.

No adjustment required

Hepatic metabolism. eGFR does not influence PPI dosing. No accumulation risk with renal impairment.

Review at 6 months

Currently essential: prior peptic ulcer + high GI-risk patient. If analgesic regimen stabilises on acetaminophen only, consider step-down to on-demand use at 6–12 months if ulcer healed and NSAID exposure has been zero.

Acetaminophen 1g TID Proposed

Analgesic · First-line

✓ Low interaction burden

No significant pharmacodynamic interaction with amlodipine or pantoprazole at doses ≤3 g/day. Does not affect BP control. Does not inhibit CYP3A4 at therapeutic doses.

⚠ If warfarin added: INR monitoring required

Not currently prescribed. Flag for future: acetaminophen >2g/day increases anticoagulant effect of warfarin. Monitor INR if anticoagulation initiated.

Dose ceiling active (eGFR 58)

Max 3 g/day (reduced from 4 g/day standard) — older adult dose ceiling. If eGFR drops <30: reduce further to 2 g/day and extend interval consideration. Current eGFR permits standard older-adult dosing.

Maintain + monitor

Step-down appropriate only if pain control goals met (NRS ≤3, functional restoration). Do not deprescribe prematurely — inadequate pain control increases functional decline and activity limitation.

Drug–drug interaction review — current and conditional regimen pairs

Amlodipine ↔ Oral NSAID

Avoid

NSAIDs impair prostaglandin-mediated vasodilation and promote sodium and water retention, opposing the antihypertensive effect of amlodipine. Documented in this patient: +18 mmHg systolic rise with diclofenac. NSAID avoidance resolves this interaction.

Amlodipine ↔ Acetaminophen

No interaction

No pharmacokinetic or pharmacodynamic interaction at therapeutic doses. Acetaminophen does not affect BP control, CCB metabolism, or renal function. Safe first-line combination.

Pantoprazole ↔ Acetaminophen

No interaction

No clinically significant interaction. Pantoprazole does not alter acetaminophen absorption or hepatic glucuronidation. Both can be safely co-prescribed at standard doses.

Pantoprazole ↔ Celecoxib (if escalated)

Required pairing

If celecoxib is initiated at escalation: concurrent PPI is mandatory per ACR guidance in high-GI-risk patients. Pantoprazole 40 mg already prescribed — adequate coverage. Do not reduce PPI dose if celecoxib is added. Monitor for breakthrough dyspepsia.

Duloxetine ↔ Amlodipine (if escalated)

Monitor

CYP2D6 involvement in duloxetine metabolism — no direct pharmacokinetic interaction with amlodipine (CYP3A4). However: duloxetine has mild BP-lowering effect which may augment amlodipine. Monitor systolic BP at initiation and at 2 weeks. Sedation risk independently documented — explicit patient counselling required before initiation.

Renal function–driven dose adjustment cascade

eGFR-dependent therapy logic — how renal function changes treatment decisions Current eGFR: 58 mL/min

CKD stage → implications for analgesic safety and dosing

eGFR Range

CKD Stage

Analgesic implications

Required action

≥60 mL/min

G1–G2 (Normal/Mild)

Acetaminophen: standard adult dose (max 4 g/day). Oral NSAIDs: conditionally permissible with GI and CV monitoring. Topical NSAIDs: safe. No dose ceiling purely on renal grounds.

Baseline monitoring. No dose adjustment needed above 60.

45–59 mL/min CURRENT

G3a (Mild–Moderate)

Acetaminophen: reduce to max 3 g/day (older adult ceiling — applies here at age 68 + eGFR 58). Oral NSAIDs: avoid unless unavoidable — prostaglandin-mediated renal perfusion increasingly dependent on baseline function. Topical NSAIDs: acceptable with close monitoring. eGFR trajectory monitoring every 6 weeks.

Active dose ceiling: APAP ≤3 g/day. NSAID avoidance recommended. Monitor eGFR 6-weekly.

30–44 mL/min

G3b (Moderate)

Acetaminophen: max 2–3 g/day. Oral NSAIDs: contraindicated — prostaglandin inhibition at this eGFR level significantly impairs autoregulation of GFR. Nephrotoxicity risk clinically meaningful. Topical NSAIDs: monitor closely — some systemic absorption occurs. Opioids: metabolite accumulation risk increases; use with caution if unavoidable.

NSAIDs now absolutely contraindicated. APAP ≤2.5 g/day. Nephrology input if further decline.

<30 mL/min

G4–G5 (Severe–Failure)

Acetaminophen: max 2 g/day with extended dosing interval (every 6–8 hours). All NSAIDs — oral and topical — absolutely contraindicated. Opioids: significant metabolite accumulation; use only with specialist oversight and dose titration. Gabapentinoids: dose reduction required per CrCl; monitor closely.

Nephrology referral mandatory. APAP ≤2 g/day. All NSAIDs stopped immediately.

Deprescribing review — medication optimisation considerations

Structured deprescribing assessment — all current medications Low polypharmacy burden — optimise before adding agents

Medication

Deprescribing rationale

Deprescribing trigger

Recommendation

Amlodipine 5 mg

CCB antihypertensive

Essential ongoing indication (hypertension). Deprescribing would destabilise BP control and increase risk from any future NSAID analgesic use. No absolute indication to stop. Age-appropriate: CCBs have favourable safety profile in older adults — not Beers-listed.

Persistent hypotension (SBP <100), orthostatic symptoms, or resolution of hypertension after significant weight loss or dietary sodium reduction. Review annually.

Maintain

No deprescribing trigger present. Annual medication review appropriate.

Pantoprazole 40 mg

PPI · GI prophylaxis

Currently appropriate: prior peptic ulcer + ongoing analgesic therapy. Risk of prolonged PPI use: hypomagnesaemia (check at 12 months if continued), Clostridioides difficile risk (low at standard doses), potential reduction in enteric calcium absorption (relevant given age). PPIs are over-used in older adults — this use is clinically justified but should not become indefinite without review.

At 6 months: review indication. If pain management achieved on acetaminophen only (no NSAID exposure), consider step-down to on-demand dosing. Repeat H. pylori testing if original ulcer had positive history — eradication changes PPI need.

Review at 6 months

Maintain while analgesic therapy is active. Re-evaluate for step-down if NSAID-free at 6-month mark.

Acetaminophen 1g TID

Analgesic (proposed)

Indication-driven agent — deprescribing appropriate only on clinical response. Do not deprescribe before adequate trial (minimum 4–6 weeks on fixed schedule). Premature stopping on partial response prevents proper efficacy assessment. Functional restoration is the endpoint, not time-based withdrawal.

Step-down to BD dosing if NRS ≤3 sustained for 4+ weeks and functional goals met. PRN use only if pain remains consistently ≤2/10. If fully resolved: stop with patient agreement and reassess at 4 weeks off treatment.

Maintain through trial

Premature deprescribing undermines the therapeutic assessment. Outcome-driven.

Adherence risk and medication optimisation

Adherence risk

Documented barrier: Prior inconsistent PRN analgesic use — patient reports forgetting doses when pain is mild. Inconsistent use of topical diclofenac due to bilateral application difficulty. Good adherence to amlodipine and pantoprazole (confirmed by pharmacy records) — suggests adherence is regimen-complexity-dependent, not general non-compliance.
Clinical implication: Fixed TID schedule (rather than PRN) removes the dose-decision burden and matches the pattern of successful adherence with amlodipine. Do not escalate analgesic dose before confirming fixed-schedule adherence is established — apparent treatment failure may be adherence failure.

Adherence pattern is self-reported only. No pharmacy dispensing frequency, blister pack audit, or caregiver confirmation available at this stage. Reliability of the adherence history should be treated as moderate at best until confirmed at the Week 2 review. Escalation decisions made before Week 2 adherence confirmation carry meaningful misclassification risk.

Fixed TID schedule Blister packs Confirm at week 2 Pharmacy dispense check

Monitoring intensity after medication changes

Polypharmacy assessment should be reviewed whenever the regimen changes. Any new prescribing should trigger re-evaluation of the full drug–drug interaction and renal dose profile.

Step 8

Evidence Layer

Guideline alignment and evidence grading supporting the recommendation — confidence basis for clinical use.

Guideline alignment & confidence summary

ACR 2023 · Strong recommendation NICE CG177 · Conditional AGS Beers Criteria 2023 · Compliant Moderate–High evidence overall GI risk literature considered Renal monitoring recommended

Evidence confidence — by domain

Analgesic efficacy in OA High

GI safety vs. NSAIDs High

Efficacy in age ≥65 High

Long-term safety (>2yr) Moderate

Functional outcome (mobility) Moderate

Applicability: incomplete adherence hx Reduced

Applicability: unknown renal trend Reduced

Evidence limitations noted

Most RCTs are <12 months duration — long-term efficacy data in chronic OA is limited. Analgesic effect size is modest (NRS reduction ~1.5–2.0). Evidence base primarily addresses pain outcomes; functional mobility improvement data is mixed. Guideline confidence remains moderate-to-high for this patient profile given NSAID contraindication.

Real-world caveat: RCT populations assume verified adherence and documented medication histories. This patient's incomplete adherence record and absent renal baseline reduce the direct applicability of trial-derived efficacy estimates. Outcomes at Week 4 may underestimate true pharmacological response if adherence was subtherapeutic.

Clinical Guidelines

Systematic Reviews

Randomized Trials

High

Overall evidence level

Source Type Level Relevance

ACR/Arthritis Foundation Guideline for Osteoarthritis · 2023

Strong recommendation for acetaminophen; conditional for topical NSAIDs in patients with high GI risk.

Supports recommendation OA · GI risk

Guideline

High

Fletcher et al. — Acetaminophen for OA Pain · 2018

RCT showing acetaminophen superior to placebo for knee OA pain with good tolerability in older adults.

Supports recommendation Age ≥65 · Tolerability

RCT

High

Cochrane Review: Topical NSAIDs for OA · 2021

Topical NSAIDs provide pain relief with lower risk of systemic adverse effects than oral NSAIDs.

Supports conditional option Topical · Systemic risk

Review

Moderate

Choosing Wisely Campaign · 2022

Avoid long-term high-dose NSAIDs in older adults with high GI risk. Supports stepwise analgesic approach.

Supports NSAID avoidance High-dose NSAIDs · Older adults

Guideline

High

AGS Beers Criteria · 2023 Update

Explicit recommendation against oral NSAIDs in adults ≥65 unless alternatives are inadequate.

Drives NSAID exclusion Age ≥65 · NSAIDs

Guideline

High

View all references (13)

Communication

Clinical Handoff

Structured communication outputs for handoffs, escalations, and team coordination.

Generated from current patient parameters

CS-2026-00841 · May 2026 · M. Evteev

Pharmacist Output

Pharmacist Recommendation Summary

Case CS-2026-00841 · 68 y/o F · Chronic OA Pain · High GI Risk

Recommendation

Primary: Acetaminophen 500–1000 mg TID (fixed schedule) — not PRN. Maximum 3 g/day given age and renal status.

Decision state: Best available balance NSAIDs contraindicated across GI, renal, and BP axes. Acetaminophen is the appropriate first-line agent within current constraints.

Rationale: Prior peptic ulcer, two NSAID failures (GI + BP intolerance), eGFR 58, and age ≥65 (Beers flag) collectively close the NSAID pathway. Opioids declined — sedation risk, patient refusal.

Active Contraindications

NSAIDs (all): CONTRAINDICATED — high GI risk (peptic ulcer Hx), prior GI + BP intolerance ×2, eGFR 58 (borderline), age ≥65 (Beers).

Opioids: AVOID — high sedation risk, patient expressly refuses, fall-risk profile, renal impairment limits metabolite clearance.

Acetaminophen dose ceiling: 3 g/day maximum. Do not exceed. Monitor LFTs at Week 4–6 if at upper limit.

Conditional Options — If Inadequate Relief

Topical diclofenac gel Conditional — Add if NRS ≥6 at Week 2. Right knee priority. Avoids systemic NSAID exposure. Confirm no open skin lesions.

Duloxetine 30 mg daily Escalation — If neuropathic features emerge or inadequate response at Week 4. Monitor for sedation and falls (patient-expressed concern). Titrate to 60 mg after 2 weeks if tolerated.

Low-dose celecoxib + PPI Conditional — Reserve for Week 8 if above fails. Requires eGFR ≥50 confirmed at time of initiation. Close GI monitoring mandatory.

Adherence Note

Adherence concern documented

Patient has a history of inconsistent PRN use. This will limit outcome assessment at Week 4 if not corrected. Fixed TID schedule should be clearly communicated and reinforced at dispensing. Consider blister packaging. If PRN pattern continues at Week 2 review, reinforce schedule before dose escalation.

M. Evteev

Clinical Pharmacist · Evteev Advisory

Case CS-2026-00841 · May 2026

Monitoring Output

Monitoring Handoff Note

Case CS-2026-00841 · For incoming pharmacist / clinical team

Current Regimen

Acetaminophen 500–1000 mg TID (fixed schedule). Initiated at last review. Week 2 check due.

Existing medications: Amlodipine 5 mg daily (HTN), Pantoprazole 40 mg daily (GI prophylaxis — maintain).

Priority Monitoring Items

Renal function (eGFR) — Baseline 58. Track trajectory. If drops >10% or eGFR <50: eliminate all NSAID options. If <40: nephrology referral.

6-weekly

GI symptoms — Prior peptic ulcer. Any epigastric pain, black stool, hematemesis: halt analgesics and refer urgently. Do not escalate to NSAID if GI symptoms present.

Every visit

Pain score + function — NRS baseline 6/10. Target: NRS ≤3 and stair-climbing restored. If NRS ≥5 at Week 4 on fixed schedule: escalate per pathway.

Every 2–4 weeks

Adherence — Inconsistent PRN history. Confirm TID fixed schedule at this visit. If still PRN: do not escalate dose — reinforce first. Consider blister packaging.

Every visit

Liver function (ALT/AST) — If acetaminophen ≥2.5 g/day or alcohol reported. ALT >3× ULN: reduce to 2 g/day. If persistent: hepatology.

Week 4–6

Blood pressure — SBP baseline 128. If any NSAID trial initiated: BP check at 2 weeks. SBP >160 → discontinue NSAID component immediately.

4–6 weekly

Escalation Triggers — Action Required

NRS ≥6 at Week 2 → Add topical diclofenac gel. Confirm no open skin lesion.

NRS ≥5 at Week 4 on confirmed fixed schedule → Escalate pathway. Notify supervising clinician.

eGFR <50 at any review → Absolute NSAID contraindication now applies. Document and notify.

GI bleed suspected → Stop all analgesics. Urgent GI referral. Do not restart without specialist clearance.

M. Evteev — Outgoing Reviewer

Handoff to: Incoming clinical pharmacist

May 2026

Urgent Communication

Escalation Summary

Case CS-2026-00841 · For supervising physician / team lead

Escalation pathway — conditions met

Two NSAID trials failed (GI + BP intolerance). Current acetaminophen monotherapy is appropriate first-line but has a limited analgesic ceiling. Pathway review due at Week 4 if pain uncontrolled.

Reason for Escalation Review

Failed therapies: Ibuprofen (GI intolerance) and diclofenac (GI + BP elevation +18 mmHg). Two NSAID classes exhausted — documented intolerance on chart.

Current treatment: Acetaminophen TID — initiated. Adequate analgesic ceiling may be insufficient at NRS 6/10.

Next escalation decision: If NRS ≥5 at Week 4 on confirmed fixed schedule — pathway review required. Options constrained by active contraindications.

Constrained Escalation Options

High-dose NSAIDs — Prior GI intolerance ×2, peptic ulcer, eGFR 58, age ≥65

CONTRAINDICATED

Opioids — Sedation risk, patient refusal, renal impairment, fall-risk age

AVOID

Topical diclofenac — Minimal systemic exposure, avoids GI pathway

Viable — add if NRS ≥6

Duloxetine 30 mg — If neuropathic component identified. Sedation monitoring required.

Escalation — Week 4

Celecoxib low-dose + PPI — Only if eGFR confirmed ≥50. Mandatory GI monitoring.

Conditional — Week 8

Pharmacist Recommendation to Supervising Physician

Reviewing pharmacist recommends proceeding with acetaminophen TID at current dose. Escalation decision deferred to Week 4 pending confirmed adherence and pain response.

If pain inadequate at Week 4: topical diclofenac addition appropriate as next step. Recommend attending physician review before initiating any systemic NSAID class given documented intolerance and current renal profile.

Orthopedic referral threshold: functional decline despite optimized pharmacotherapy.

M. Evteev

Clinical Pharmacist — requesting physician review

Case CS-2026-00841 · May 2026

Physician Communication

Attending Physician Brief

Case CS-2026-00841 · Concise summary for physician review

Patient Context

68-year-old female. Chronic OA pain, bilateral knees. NRS 6/10. Goal: restore stair-climbing capacity and walking (>15 min).

Relevant comorbidities: HTN (controlled, amlodipine), CKD G2 (eGFR 58), prior peptic ulcer (healed >1yr), inconsistent PRN adherence pattern.

Pharmacist Decision

Initiated: Acetaminophen 500–1000 mg TID (fixed schedule). Maximum 3 g/day.

NSAIDs: avoided — GI intolerance ×2 (ibuprofen, diclofenac), peptic ulcer Hx, eGFR 58, age ≥65, prior diclofenac BP elevation (+18 mmHg).

Evidence alignment: ACR 2023 strong recommendation. Beers Criteria compliant. Moderate–high evidence base.

Items Requiring Physician Awareness

Analgesic ceiling of acetaminophen monotherapy may be insufficient (NRS 6/10 at baseline). Escalation pathway mapped — review due Week 4.

If escalation required beyond topical diclofenac, all systemic NSAID options require physician authorization given documented intolerance and renal profile.

Adherence gap documented — PRN pattern. Outcome assessment at Week 4 may be unreliable if not corrected.

If eGFR falls below 50 at next check: all NSAID use absolutely contraindicated. Pharmacist will notify physician. Requires nephrology co-management if eGFR <40.

Physician Action Requested

Review and countersign pharmacist recommendation if in agreement. If Week 4 escalation required: physician review before any systemic NSAID trial. Orthopedic referral at physician discretion if conservative management ceiling is reached.

M. Evteev — Clinical Pharmacist

For review: Attending Physician

CS-2026-00841 · May 2026

Medication Safety

Medication Risk Summary

Case CS-2026-00841 · Analgesic risk profile — structured for safety review

Active Risk Flags

GI bleeding risk — Prior peptic ulcer + 2 prior NSAID GI intolerances

HIGH

Renal impairment — eGFR 58 (CKD G2), trajectory uncertain

MODERATE

Cardiovascular — Controlled HTN, prior NSAID-related BP elevation ×1

MODERATE

Sedation / falls — Age ≥65, patient refuses sedating agents, high fall concern

MODERATE

Adherence — Documented inconsistent PRN pattern, subtherapeutic exposure expected

MODERATE

Analgesic ceiling — Acetaminophen monotherapy may be insufficient at NRS 6/10

MONITOR

Absolute Contraindications — Current Profile

NSAIDs (systemic, all classes) — GI risk + documented intolerance ×2 + renal borderline + Beers flag

Opioids — Sedation risk + patient refusal + fall risk + renal clearance concern

High-dose acetaminophen (>3 g/day) — Renal and hepatic caution; age-related sensitivity

Duloxetine — Not contraindicated but sedation monitoring required; patient has expressed concern

Risk Interactions — Existing Medications

Amlodipine 5 mg — Risk: NSAIDs can impair antihypertensive efficacy. Avoid concurrent NSAID use without BP monitoring. BP target: SBP <140.

Pantoprazole 40 mg — Currently appropriate as GI prophylaxis. Maintain throughout any analgesic escalation. If any NSAID added: do not discontinue PPI.

Acetaminophen 3 g/day ceiling — Confirm patient not using OTC analgesics with acetaminophen content (combination cold/flu products, etc.). Counsel on total daily dose limit.

Safety Review Status

Beers Criteria 2023 compliant. ACR 2023 guideline aligned. No current medications flagged for inappropriate prescribing in age ≥65 given current selection.

Complexity score: 72 / 100 (High). Multi-axis contraindication profile. Analgesic pathway narrowed but not closed. Monitoring burden: elevated.

M. Evteev

Medication Safety Review · Clinical Pharmacist

CS-2026-00841 · May 2026

Treatment Documentation

Treatment Change Rationale

Case CS-2026-00841 · Documented reasoning for analgesic selection decision

Clinical Indication

Chronic osteoarthritis pain, bilateral knees. NRS 6/10 at baseline. Functional limitation: unable to climb stairs, walking restricted to <10 min. Patient goals: mobility restoration, pain reduction to functional level (NRS ≤3).

Prior Therapy History — Reason for Change

Ibuprofen (NSAID): Discontinued — GI intolerance. Epigastric pain, nausea. Prior peptic ulcer risk compounded GI concern.

Diclofenac (NSAID): Discontinued — GI intolerance + BP elevation +18 mmHg systolic. Amlodipine efficacy transiently impaired.

Conclusion: Two NSAID classes exhausted due to documented intolerance. Class-wide NSAID contraindication now applies in this patient. Any future NSAID consideration requires senior physician authorization and mandatory GI + BP monitoring.

Rationale for Current Selection — Acetaminophen TID

Acetaminophen selected as appropriate first-line within current constraint profile. Rationale:

Avoids GI risk pathway — no prostaglandin inhibition. Safe in prior peptic ulcer history.

Avoids CV/BP risk — no antihypertensive interaction. Amlodipine efficacy preserved.

Renal safety — acceptable at eGFR 58. Dose ceiling maintained at 3 g/day.

ACR 2023 guideline aligned — strong recommendation for acetaminophen in OA with high GI risk. Beers Criteria 2023 compliant.

Limitation: analgesic ceiling may be insufficient at NRS 6/10. Escalation pathway defined and documented.

Why Not Alternative Agents

High-dose NSAIDs: Contraindicated — GI intolerance ×2 documented, peptic ulcer Hx, age ≥65 (Beers), eGFR 58 (borderline). Risk-benefit unfavorable.

Opioids: Not appropriate for chronic OA in this profile — fall risk, patient refusal, renal metabolite clearance concern, dependency risk in older adult without specialist oversight.

Duloxetine: Held — no neuropathic component confirmed at this stage. Sedation monitoring concern (patient-expressed). Reserved for Week 4 escalation if indicated.

M. Evteev

Clinical Pharmacist · Treatment change documented

CS-2026-00841 · May 2026

Follow-up

Follow-up Monitoring Priorities

Case CS-2026-00841 · For next clinical contact — structured review agenda

Week 2 Review — Priority Agenda

Adherence check — Confirm TID fixed schedule (not PRN). Document missed doses. If PRN pattern continues: reinforce before any dose change.

Week 2 · Priority

Pain score (NRS) — Baseline 6/10. If NRS ≥6 on confirmed TID schedule → add topical diclofenac gel (right knee priority). Do not escalate systemic agent.

Week 2

GI symptom check — Any epigastric pain, nausea, black stool. If any GI symptom: halt analgesics, refer urgently. Do not proceed to escalation while GI symptoms present.

Week 2

Stair use + walking distance — Target: stair climbing restored, walking >15 min. Document functional change from baseline for Week 4 comparison.

Week 2

Week 4–6 — Decision Checkpoint ★

★

Labs required: eGFR, creatinine, LFT (ALT/AST), BP. These results determine whether escalation is viable. Do not initiate celecoxib without eGFR ≥50 confirmed.

Week 4–6

Pain + function review — If NRS ≥5 on fixed schedule: escalation decision. Notify physician. Pathway defined: topical → duloxetine → celecoxib+PPI (physician authorization required).

Week 4

Neuropathic screen — Burning, radiating pain, night symptoms? If yes: duloxetine 30 mg escalation is appropriate. Requires sedation and fall-risk counseling before initiation.

Week 4

Longitudinal Concerns — Keep in View

Renal trajectory — eGFR 58. Not currently critical but declining trend would close further escalation options. Annual check minimum; more frequent if any NSAID considered. Note: no prior eGFR available — trajectory direction unconfirmed. First recheck at Week 6 will establish baseline trend.

Adherence pattern — If PRN use continues to Month 3 review, consider dosette box or carer-assisted schedule. Subtherapeutic exposure confounds outcome assessment. Adherence at initiation is self-reported only — Week 2 check is the first objective data point.

Functional independence — Primary patient goal. If no improvement by Month 3 despite adequate analgesia: physiotherapy referral (home-based, transport barrier documented). Orthopedic threshold: TKA candidacy discussion.

Prior NSAID intolerance — documented via patient report and partial chart record. Ibuprofen GI event details sparse. Diclofenac BP response better documented. Intolerance history is clinically assumed as documented but may benefit from source record retrieval before any future NSAID consideration.

Annual review: full metabolic panel, medication safety review, falls and ADL reassessment. Reassess surgical threshold. Analgesic pathway may narrow further as renal function declines with age.

M. Evteev

Follow-up agenda prepared · May 2026

Next contact: Week 2 · CS-2026-00841

Documents are generated from current patient parameters. Content adapts when parameters change. Review and apply clinical judgment before use in patient care or formal handoff.

Case Summary

Patient 68 y/o · F

Condition Chronic OA · Bilateral knees

Pain (NRS) 6 / 10

eGFR 58 mL/min

GI risk High

NSAID pathway CLOSED

Complexity 72 / 100

Recommendation Acetaminophen TID

Active Constraints

NSAIDs Contraindicated

Opioids Avoid

Sedating agents Patient refuses

Topical NSAID Conditional

Duloxetine Escalation

Next Clinical Actions

Week 2 Adherence + NRS

Week 4–6 Labs + escalation decision

Month 3 Comprehensive review

Annual Safety review + eGFR

Evidence Basis

ACR 2023 Strong rec

Beers 2023 Compliant

NICE CG177 Conditional

Overall evidence Moderate–High

Clinical Decision Infrastructure

Workflow Library

Clinstrux supports pharmacist and clinician decision-making across multiple clinical domains. Each workflow integrates patient parameters, clinical reasoning, and evidence-based recommendations in a single interactive interface.

Workflows

Clinical sections

Live

Parameter editing

Available workflows

3 of 3

Pain Management · Medication Review

Chronic Osteoarthritis
Analgesic Safety Review

Pharmacist-led medication review for a high-complexity OA case with intersecting GI, renal, and cardiovascular constraints. The NSAID pathway is closed on multiple grounds — the workflow reasons through the remaining options and documents the clinical basis for the recommendation.

What you'll assess

Analgesic risk stratification under compound contraindications

Renal dosing, GI safety, and polypharmacy burden

Longitudinal trajectory across 5 timepoints

NSAID pathway closed CKD Stage 3a Polypharmacy risk Acetaminophen TID

68 y/o Female · CS-2026-00841 8 sections

Open workflow

Antimicrobial Stewardship · Inpatient Review

Antibiotic Stewardship
Therapy Review

Day 3 inpatient antimicrobial review integrating inflammatory markers, clinical trajectory, and culture data. Demonstrates how Clinstrux supports IV-to-oral de-escalation decisions — with clinical improvement weighted appropriately against laboratory values.

What you'll assess

WBC, CRP, temperature, and clinical trajectory integration

IV-to-oral step-down logic and de-escalation criteria

Culture-guided therapy adjustment and renal dose review

WBC · CRP · Temp De-escalation logic Renal dose check Clinical trajectory

72 y/o Male · CS-2026-00842 4 sections

Open workflow

Medication Optimisation · Polypharmacy Review

Polypharmacy &
Medication Burden Review

Structured medication review for an older adult carrying eleven concurrent medications. Evaluates anticholinergic burden, falls risk, duplicate therapy, and deprescribing opportunities using a clinical reasoning framework.

What you'll assess

Anticholinergic and CNS depressant burden scoring

Drug interactions, duplicate therapy, and regimen complexity

Deprescribing targets and medication optimisation plan

11 medications Falls risk elevated Anticholinergic burden Deprescribing targets

81 y/o Female · CS-2026-00843 4 sections

Open workflow

Live parameter editing

Clinical Impression layer

Longitudinal tracking

Evidence-referenced output

Handoff documentation

Day 3 of IV piperacillin-tazobactam

Renal dose adjustment active

Culture data pending

I — Patient Context

II — Clinical Assessment

III — Decision & Monitoring

Step 1

Patient & Lab Parameters

Current antimicrobial regimen, inflammatory markers, and clinical status. Adjust any value to update the stewardship assessment.

WBC (×10⁹/L)

14.2

Elevated

CRP (mg/L)

Elevated · trending down

eGFR (mL/min)

Mild impairment

Temperature (°C)

37.4

Afebrile

Clinical Improvement

Improving

Tolerating oral intake · mobilising

Culture / Sensitivity Data

Pending

Blood cultures day 1 — no growth to date

Parameters are pre-populated for demonstration. All values update the stewardship assessment in real time.

Step 2

Stewardship Assessment

Clinical reasoning layer — interpreting lab trends, trajectory, and culture data together.

Clinical Status Summary

Antimicrobial Review — Day 3

Clinical improvement noted

Inflammatory Trend

Improving

WBC 14.2 · CRP 88

Fever Status

Afebrile

37.4°C — resolved

Clinical Trajectory

Improving

Tolerating oral · mobilising

Renal Status

Mild impairment

eGFR 52 — dose adj. active

Overall Assessment

Patient demonstrates meaningful clinical improvement on Day 3 of IV piperacillin-tazobactam. Inflammatory markers remain elevated but are trending in the right direction. Defervescence achieved. Clinical improvement is the dominant stewardship signal at this stage.

Clinical Impression Day 3 Review

Clinical direction

Assessment is generated from current parameters. Clinical judgment must be applied before any antimicrobial decision.

Step 3

Stewardship Recommendation

Primary recommendation with rationale and supporting considerations.

Stewardship recommendation · Day 3 review

Consider
De-escalation

Clinically supported

Patient is clinically improving with defervescence, tolerating oral intake, and mobilising. Inflammatory markers remain elevated but are on a downward trend. In the context of clinical improvement, sustained elevated CRP alone is not a contraindication to de-escalation. Oral step-down to amoxicillin-clavulanate should be considered if culture data supports a sensitive organism or no growth at 72 hours.

IDSA Stewardship Principles Clinical improvement outweighs markers Culture data awaited Renal dose adjustment maintained

76%

Moderate-high confidence

Clinical trajectory supports de-escalation · pending culture confirmation

De-escalation target

Oral amoxicillin-clavulanate
If no resistant organism

Prerequisite

72-hr culture result
No growth or sensitive organism

Duration target

5 days total (CAP)
Per IDSA/ATS 2019 guidance

Stewardship decision logic

Reasoning — why each option was considered or declined

Continue IV therapy Conditional

Appropriate if clinical deterioration or culture reveals resistant organism.

Continued IV exposure carries line-related infection risk — minimise duration

IV-to-oral step-down is supported once clinical stability criteria met

Reserve for non-responders or confirmed resistant organisms

De-escalate to oral Preferred

Clinical improvement is the primary trigger for IV-to-oral step-down.

Defervescence achieved — afebrile 37.4°C

Tolerating oral intake and mobilising — oral bioavailability acceptable

Await culture result before finalising — no growth likely supports narrow-spectrum oral

Escalate therapy Not indicated

No clinical or microbiological trigger for escalation at this review.

Patient is improving — escalation without deterioration is not stewardship-appropriate

No resistant organism confirmed in culture

Reserve for documented treatment failure or resistant pathogen

Stewardship recommendations require clinical validation. This is a decision-support tool, not a prescribing system.

Step 4

Monitoring Parameters

Ongoing safety and efficacy monitoring requirements for the current antimicrobial regimen.

Current regimen day

Day 3

IV pip-tazo 4.5 g TDS

Culture result

Pending

De-escalation contingent on result

Renal monitoring

Active

eGFR 52 — dose adjusted

Monitoring schedule

Checkpoint

Labs / tests

Clinical assessment

Action trigger

72hr ★

Culture result, eGFR recheck, WBC, CRP

Clinical trajectory, fever status, oral tolerance

Culture + improvement → step down. Resistant organism → escalate. Deterioration → urgent review.

Daily

Temperature, WBC if clinically indicated

Fever, organ function, oral tolerance, mobility

New fever or deterioration → do not step down. Escalate and review culture urgently.

Day 5 (target)

End-of-treatment CRP, WBC if required

Reassess need for further antimicrobial therapy

Total 5-day course per IDSA/ATS CAP guidance. Stop if goals met.

Renal dosing — current eGFR

Piperacillin-tazobactam

4.5 g TDS (eGFR 30–59)

Dose interval extended per renal guidance. Standard dose 4.5 g QDS at eGFR ≥60.

If oral step-down: Co-amoxiclav

625 mg TDS (eGFR ≥30)

Standard dosing applicable at current eGFR. No adjustment required for co-amoxiclav at eGFR 52.

Monitoring requirement

eGFR recheck at 72hr

Acute illness may cause transient renal deterioration. Recheck before extending course beyond 5 days.

Flags & safety considerations

⚠ Culture-negative at 72hr — reassess empirical spectrum. Consider narrowing if clinical picture supports.

⚠ Prolonged IV access increases line infection risk — transition to oral as soon as clinical criteria met.

⚠ eGFR 52 — monitor for acute kidney injury during course. Stop all nephrotoxic agents if eGFR falls >20%.

ℹ Document indication, intended duration, and review date in clinical notes at each contact — stewardship standard.

Monitoring schedule is illustrative. Adapt to local antimicrobial stewardship policy and patient-specific factors.

11 concurrent medications

Falls risk: elevated

Anticholinergic burden: high

I — Patient Context

II — Clinical Assessment

III — Decision & Plan

Step 1

Medication Profile

Current medication burden indicators. Adjust any parameter to update the polypharmacy assessment in real time.

Total Medications

Hyper-polypharmacy

High-Risk Medications

Warfarin · opioid · hypnotic

Drug Interactions

2 clinically significant

Duplicate Therapy

Yes

Dual antihypertensive overlap

Anticholinergic Burden (ACB Score)

High — oxybutynin + amitriptyline + promethazine

Falls Risk (Medication-Related)

High

Opioid + hypnotic + antihypertensive

Current medication list

Medication

Indication

Risk flag

Review priority

Warfarin 3 mg daily

AF — stroke prevention

High-risk · INR monitoring

Routine INR review

Oxybutynin 5 mg BD

Overactive bladder

ACB +3 · Falls · Cognitive risk

Deprescribing candidate

Amitriptyline 25 mg nocte

Neuropathic pain / sleep

ACB +2 · Falls · Sedation

Deprescribing candidate

Zopiclone 7.5 mg nocte

Insomnia

Falls · Dependence risk

Taper and withdraw

Tramadol 50 mg QDS

Chronic pain

Falls · Serotonin risk (+ SSRI)

Review indication urgently

Sertraline 100 mg daily

Depression

Serotonin risk (+ tramadol)

Interaction review

Amlodipine 10 mg daily

Hypertension

Duplicate class (+ ramipril)

Confirm dual indication

Ramipril 10 mg daily

Hypertension / renal protection

Standard monitoring

Continue — review K⁺

Metformin 1 g BD

Type 2 diabetes

eGFR monitoring required

Continue — check renal function

Alendronic acid 70 mg weekly

Osteoporosis

Administration technique review

Confirm adherence

Omeprazole 20 mg daily

GI protection

Indication review (long-term)

Review ongoing need

Medication list is pre-populated for demonstration. Adjust burden indicators above to update the assessment in real time.

Step 2

Burden Assessment

Clinical reasoning layer — interpreting medication burden, risk indicators, and deprescribing opportunities.

Clinical Status Summary

Medication Optimisation Review — May 2026

High burden — review required

Medication Burden

Hyper-polypharmacy

11 medications · ≥10 threshold

Anticholinergic Load

High (ACB 5)

Threshold ≥3 — cognitive risk

Falls Risk

Elevated

3 FRIDs · opioid + hypnotic + AHT

Interaction Risk

Moderate–High

4 interactions · 2 significant

Overall Assessment

Patient carries a high medication burden with eleven concurrent agents including multiple high-risk medications and a significantly elevated anticholinergic load. The current regimen presents compound risk across falls, cognition, serotonin toxicity, and anticoagulation. Structured deprescribing review is indicated.

Clinical Impression Medication Review · May 2026

Clinical direction

Assessment updates in real time as parameters change. Clinical judgment must be applied to all deprescribing decisions.

Step 3

Optimisation Recommendations

Prioritised deprescribing and medication optimisation actions.

Pharmacist recommendation · Medication review May 2026

Structured
Deprescribing Review

Urgent — multiple targets identified

The current regimen carries compound risk across multiple axes — elevated anticholinergic burden, significant falls risk, a clinically important serotonin interaction, and duplicate antihypertensive therapy. Three medications have been identified as primary deprescribing candidates (oxybutynin, zopiclone, amitriptyline) alongside one urgent interaction requiring management. A structured, stepwise review is indicated — addressing the highest-risk agents first while monitoring for symptom rebound.

STOPP/START v3 criteria AGS Beers Criteria 2023 Serotonin interaction — action required ACB ≥3 — cognitive risk

91%

High confidence

Multiple STOPP criteria met · immediate deprescribing targets identified

Prioritised deprescribing targets

Priority 1 — Urgent

Tramadol + Sertraline

Clinically significant serotonin syndrome risk. Concurrent use warrants urgent review — consider switching tramadol to an alternative analgesic class with lower serotonergic potential.

Review analgesic — switch away from tramadol

Priority 2 — High

Oxybutynin 5 mg BD

ACB score +3. Contributes substantially to anticholinergic burden. Associated with cognitive impairment, falls, urinary retention, and constipation in frail older adults. Consider mirabegron as a lower-burden alternative or non-pharmacological bladder training.

Switch to mirabegron or initiate bladder training

Priority 3 — High

Zopiclone 7.5 mg nocte

Z-drug hypnotics are a recognised FRID and Beers/STOPP criterion in older adults. Risk of falls, cognitive impairment, and physical dependence. Initiate gradual taper over 4–6 weeks with sleep hygiene support.

Structured taper — 25% dose reduction every 2 weeks

Priority 4 — Review

Amitriptyline 25 mg nocte

ACB score +2. Tricyclic antidepressants are a STOPP criterion in older adults. If prescribed for neuropathic pain, consider switching to gabapentin or duloxetine. If for sleep, address as part of zopiclone withdrawal plan.

Review indication — consider gabapentin or duloxetine switch

Priority 5 — Confirm

Dual antihypertensive (amlodipine + ramipril)

Dual antihypertensive therapy may be intentional (BP target not met on monotherapy) or represent duplicate prescribing. Confirm current BP readings and target. If BP is at goal, consider stepping down to monotherapy.

Check recent BP readings — confirm dual therapy indication

Deprescribing should be patient-led and stepwise. Do not stop multiple medications simultaneously. Confirm patient goals and preferences before any change.

Step 4

Monitoring & Follow-Up

Review schedule, monitoring parameters, and patient safety considerations for the deprescribing plan.

Deprescribing targets

Identified for review or withdrawal

Urgent actions

Tramadol + sertraline interaction

Review timeline

4–8 weeks

Stepwise — one change at a time

Follow-up schedule

Checkpoint

Action

Monitoring parameters

Decision trigger

Within 48hr ★

GP/prescriber review of tramadol + sertraline interaction

Symptom review — agitation, tremor, hyperthermia

Switch tramadol to alternative — do not delay if symptomatic

Week 1–2

Initiate zopiclone taper. Discuss oxybutynin switch with patient.

Sleep quality, falls incidents, bladder symptoms

If sleep significantly worsens, slow the taper rate. Document patient preference.

Week 4

Review oxybutynin switch outcome. Reassess amitriptyline indication.

ACB score recheck, falls risk reassessment, cognition

Target ACB score reduction ≥2. Confirm bladder symptom control on new agent.

Week 8

Full medication reconciliation. Review all changes made.

Full medication count, BP, HbA1c, renal function, falls log

Target: ≤8 medications. Document outcomes and further optimisation opportunities.

Safety monitoring requirements

Active flags

⚠ Tramadol + sertraline: serotonin syndrome risk — monitor for agitation, confusion, tremor, hyperthermia. Escalate immediately if signs present.

⚠ Warfarin: any new or stopped medication may affect INR. Recheck INR within 5–7 days of any regimen change.

⚠ Zopiclone taper: watch for rebound insomnia and withdrawal anxiety. Slow the taper if symptoms are distressing — do not abruptly discontinue.

⚠ Falls risk remains elevated until high-risk medications are successfully reduced. Ensure falls prevention measures are in place during the transition period.

ℹ Document patient goals and preferences before each medication change. Deprescribing should be a shared decision — patient agreement is essential.

ℹ Metformin: confirm eGFR ≥45 at next renal review. Withhold temporarily if contrast media or acute illness.

Monitoring schedule is illustrative. Adapt to patient circumstances, local protocols, and prescriber agreement.